New pill could tame tough psoriasis without injections
NCT ID NCT07326813
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests D-2570, a new daily pill, in 477 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570, an active comparator (BMS-986165), or a placebo. The study measures how well the drug clears skin and improves quality of life over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D-2570 tablet
- What this could lead to
- If successful, D-2570 could offer a new oral treatment option for people with moderate to severe plaque psoriasis.
- What could go wrong
- This is a Phase 3 trial, but results are not yet known. The drug may not work better than existing treatments or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Skin Disease Hospital
RECRUITINGShanghai, Shanghai Municipality, 200443, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial